Jackson Andrew C.'s Form 4 filing
Calidi Biotherapeutics, Inc. (CLDI) · filed Aug 25, 2025
- Accession no.
- 0001641172-25-025445
- Filed
- Aug 25, 2025
- Trade date
- Aug 21, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $5.00K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jackson Andrew C.CIK 0001636738 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | Common Stock | PPurchaseAcquired | +2,500 | $2.00F2 | +$5,000 | 2,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | Common stock | PPurchaseAcquired | +2,500 | –F2 | – | 2,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.